MIT Technology Review Subscribe

Rx tester

A printed device simulates cancer treatments on biopsied tissue.

A 3D-printed microfluidic device that simulates cancer treatments on biopsied tumor tissue could help clinicians assess how individual patients will respond to different drugs—before administering a single dose.

Designed by MIT and Draper researchers, the device is the size of a quarter and can be printed at low cost in about an hour. It is made of a biocompatible resin that’s commonly used to make mouth guards. While other printable resins typically kill cells quickly, this near-transparent resin supports long-term survival of biopsied tissue and prints in very high resolution.

Advertisement

Tumor fragments are injected into the device, whose three cylindrical “chimneys” act as ports to introduce and drain fluids, such as cancer-fighting agents and nutrients for the tissue. These chimneys also remove air bubbles that might disrupt the experiment. Clinicians can use imaging techniques to see in real time how the tumor tissue responds to different drugs.

This story is only available to subscribers.

Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.

Subscribe now Already a subscriber? Sign in
You’ve read all your free stories.

MIT Technology Review provides an intelligent and independent filter for the flood of information about technology.

Subscribe now Already a subscriber? Sign in

A promising application is immuno­therapy, where certain drugs rev up a patient’s immune system to fight cancer. “You can envision a future where your doctor will have a 3D printer and can print out the devices as needed,” says co-inventor Luis Fernando Velásquez-García of the Microsystems Technology Laboratories. “You can run multiple tests in parallel and figure out what would work best with the patient’s biological makeup.”

This is your last free story.
Sign in Subscribe now

Your daily newsletter about what’s up in emerging technology from MIT Technology Review.

Please, enter a valid email.
Privacy Policy
Submitting...
There was an error submitting the request.
Thanks for signing up!

Our most popular stories

Advertisement